Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)
Close on Nov 17, 2026Market cap $1.78BP/E –Yield –
Agios Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Agios Pharmaceuticals's cash was $1.00B at Jun 30, 2026. For fiscal 2025 it was $1.20B, down 20.0% from the year before. Over ten years it grew 12.3% a year on average. The highest annual figure on record is $1.50B in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20B | -20.0% |
| FY2024 | Dec 31, 2024 | $1.50B | +86.0% |
| FY2023 | Dec 31, 2023 | $806.40M | -26.7% |
| FY2022 | Dec 31, 2022 | $1.10B | -14.5% |
| FY2021 | Dec 31, 2021 | $1.29B | +91.9% |
| FY2020 | Dec 31, 2020 | $670.50M | -6.6% |
| FY2019 | Dec 31, 2019 | $717.80M | -10.9% |
| FY2018 | Dec 31, 2018 | $805.40M | +41.8% |
| FY2017 | Dec 31, 2017 | $567.80M | -1.0% |
| FY2016 | Dec 31, 2016 | $573.60M | +52.6% |
| FY2015 | Dec 31, 2015 | $375.90M | -19.6% |
| FY2014 | Dec 31, 2014 | $467.40M | +141.1% |
| FY2013 | Dec 31, 2013 | $193.90M | +51.5% |
| FY2012 | Dec 31, 2012 | $127.98M | +8.8% |
| FY2011 | Dec 31, 2011 | $117.66M | +51.1% |
| FY2010 | Dec 31, 2010 | $77.88M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.00B | -23.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.00B | -28.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.20B | -20.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.30B | -23.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.30B | +101.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.40B | +96.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.50B | +86.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.70B | +94.9% |
| Q2 FY2024 | Jun 30, 2024 | $645.30M | -31.9% |
| Q1 FY2024 | Mar 31, 2024 | $714.30M | -28.6% |
| Q4 FY2023 | Dec 31, 2023 | $806.40M | -26.7% |
| Q3 FY2023 | Sep 30, 2023 | $872.40M | -12.8% |
| Q2 FY2023 | Jun 30, 2023 | $946.90M | -13.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.00B | -16.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.10B | -14.5% |
| Q3 FY2022 | Sep 30, 2022 | $1.00B | -28.6% |
| Q2 FY2022 | Jun 30, 2022 | $1.10B | -35.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.20B | -50.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.29B | +91.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.40B | +93.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.70B | +114.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.40B | +291.5% |
| Q4 FY2020 | Dec 31, 2020 | $670.50M | -6.6% |
| Q3 FY2020 | Sep 30, 2020 | $722.40M | +33.7% |
| Q2 FY2020 | Jun 30, 2020 | $794.40M | +27.3% |
| Q1 FY2020 | Mar 31, 2020 | $613.10M | -13.4% |
| Q4 FY2019 | Dec 31, 2019 | $717.80M | -10.9% |
| Q3 FY2019 | Sep 30, 2019 | $540.50M | -38.5% |
| Q2 FY2019 | Jun 30, 2019 | $624.00M | -33.4% |
| Q1 FY2019 | Mar 31, 2019 | $707.80M | -28.8% |
| Q4 FY2018 | Dec 31, 2018 | $805.40M | +41.8% |
| Q3 FY2018 | Sep 30, 2018 | $878.40M | +561.7% |
| Q2 FY2018 | Jun 30, 2018 | $936.60M | +575.2% |
| Q1 FY2018 | Mar 31, 2018 | $994.70M | +396.7% |
| Q4 FY2017 | Dec 31, 2017 | $567.80M | -1.0% |
| Q3 FY2017 | Sep 30, 2017 | $132.74M | -77.1% |
| Q2 FY2017 | Jun 30, 2017 | $138.72M | – |
| Q1 FY2017 | Mar 31, 2017 | $200.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $573.60M | – |
| Q3 FY2016 | Sep 30, 2016 | $579.10M | – |
See a number that looks wrong?